Regen BioPharma (Regen BioPharma) Other Current Liabilities : $1.40 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Regen BioPharma Other Current Liabilities?

Regen BioPharma's other current liabilities for the quarter that ended in Mar. 2024 was $1.40 Mil.

Regen BioPharma's quarterly other current liabilities increased from Sep. 2023 ($1.40 Mil) to Dec. 2023 ($1.40 Mil) but then from Dec. 2023 ($1.40 Mil) to Mar. 2024 ($1.40 Mil).

Regen BioPharma's annual other current liabilities declined from Sep. 2021 ($6.89 Mil) to Sep. 2022 ($3.55 Mil) and declined from Sep. 2022 ($3.55 Mil) to Sep. 2023 ($1.40 Mil).

Regen BioPharma Other Current Liabilities Historical Data

The historical data trend for Regen BioPharma's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Other Current Liabilities Chart

Regen BioPharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Other Current Liabilities

Get a 7-Day Free Trial

Regen BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Current Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Regen BioPharma Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Regen BioPharma Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Regen BioPharma (Regen BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBPP.PFD) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

RGBP:USA

Address

4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942

Website

https://www.regenbiopharmainc.com

Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.